TT-11 is under clinical development by Tessa Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect TT-11’s likelihood of approval (LoA) and phase transition for Natural Killer Cell Lymphomas took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 08 May 2021 increased TT-11’s Phase Transition Success Rate (PTSR) for Peripheral T-Cell Lymphomas (PTCL).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TT-11 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

TT-11 overview

TT-11 is under investigation for the treatment of relapsed/refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma, anaplastic large cell lymphoma, peripheral T cell lymphoma, extranodal natural killer cell lymphomas /T-cell lymphoma, diffuse large B cell lymphoma and primary mediastinal large B-cell lymphoma (PMBCL). The therapeutic candidate is administered as intravenous injection. It acts by targeting CD30L receptors.

Tessa Therapeutics overview

Tessa Therapeutics is a clinical-stage biotechnology company that discovers, develops, and commercializes cancer immunotherapies that redirect the body’s powerful anti-viral immune response and identify and exterminate cancer cells. The company provides products for cancers including gastric carcinoma, cervical, nasopharyngeal, head, oropharyngeal, and neck cancer. It harnesses virus-specific T cell (VST) technology for the treatment of solid tumors. Tessa Therapeutics is also extending its VST platform and treat an array of solid tumors through combinatorial approaches with chimeric antigen receptors, antibodies, and oncolytic virus technologies. The company works in partnership with National Cancer Centre, Singapore; Baylor College of Medicine; and Agency for Science, Technology and Research. Tessa Therapeutics is headquartered in Singapore.

Quick View TT-11 LOA Data

Report Segments
  • Innovator
Drug Name
  • TT-11
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.